ProfileGDS5678 / 1439684_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 42% 42% 41% 41% 43% 42% 41% 40% 41% 41% 41% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.101445
GSM967853U87-EV human glioblastoma xenograft - Control 22.9626242
GSM967854U87-EV human glioblastoma xenograft - Control 32.9616342
GSM967855U87-EV human glioblastoma xenograft - Control 42.8910341
GSM967856U87-EV human glioblastoma xenograft - Control 52.8935741
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0867543
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0398442
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9312641
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9007740
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.940341
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9486241
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.91841
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9584841
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9521341